Mirum Pharma Enters $68.5M Private Placement Agreement With TCGX For 1M Shares At $68.48 Each

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor, for a private placement of 1,000,000 shares of its common stock (the "Common Stock"). The Common Stock issued to the private placement investors at closing will be priced at $68.48 per share for approximately $68.5 million in gross proceeds.

The proceeds from the private placement, together with Mirum's $200 million private placement announced earlier this month, are intended to fund clinical development and commercial activities following the previously announced proposed acquisition of Bluejay Therapeutics ("Bluejay"), a privately held biotechnology company focused on viral and liver diseases. Both private placements are expected to close concurrently with the proposed acquisition with Bluejay, anticipated in the first quarter of 2026, subject to regulatory approval and other customary closing conditions.